PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: SignaBlok, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning)
SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2012/01/10 - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to introduce company’s new approach to the prevention and treatment of sepsis (blood poisoning).

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

SignaBlok, Inc. today announced that it has been awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to establish in vivo proof of concept for Company's novel strategy to fight sepsis (blood poisoning), a serious medical condition characterized by a whole-body inflammatory state that often leads to death.

SignaBlok’s approach targets an inflammation amplifier, a specific receptor called TREM-1, inhibition of which is known to dramatically improve survival in animal models of sepsis. Company’s proprietary peptide inhibitors that are developed using a new model of cell signaling, known as the SCHOOL model, inhibit TREM-1 in a novel, ligand-independent way and possess unique and beneficial properties.

The award will support formulation development and in vivo proof-of-concept studies to evaluate the efficacy of TREM-1-specific SCHOOL peptides in either the free or nanoparticulate form. The latter was developed using SignaBlok’s proprietary nanosystem for targeted delivery of drugs and imaging agents. The most promising formulations will be selected for IND-enabling toxicology studies leading into clinical development with the eventual goal of protecting against septic shock and improving survival in sepsis.

“DARPA's support for the use of SCHOOL peptides in preventing and treating sepsis, as evidenced by this contract, is a critical recognition of our innovative approach to this disease,” stated Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok.

“Recent discoveries provide evidence that TREM-1 plays an important role in the pathogenesis of not only sepsis but also cancer and other inflammation-associated conditions such as radiation-induced multiple organ dysfunction syndrome. Thus, the DARPA funding creates a tremendous opportunity for SignaBlok to expand its portfolio of innovative technologies and establish in vivo proof of concept for these disorders, including various cancer types such as lung, breast and pancreatic cancers,” said Alexander Sigalov.

About SignaBlok
SignaBlok is developing a new class of therapies – SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok’s is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy and reduce dose. Additional information about SignaBlok is available at signablok.com.

About DARPA
The Defense Advanced Research Projects Agency (DARPA) is a component of the United States Department of Defense, focused on sponsoring revolutionary, high-payoff research bridging the gap between fundamental discoveries and their military and civilian use.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Awarded DARPA Contract to Support New Technology to Combat Sepsis

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

MDxHealth Announces Agreement with Istituto Diagnostico Varelli for Distribution of SelectMDx Throughout Central-South Italy
BD Veritor™ System Meets FDA’s New Performance Requirements for Rapid Influenza Antigen Detection Tests
Sub-Sahara Africa - Increase in Western Lifestyles Leads to Dire Need for Chronic Prescription Drugs Finds Frost & Sullivan
BD Initiates New Industry Alliance to Combat Rising Opioid Crisis
BTG and Society of Interventional Oncology to Explore Role of Minimally Invasive Therapies in Immuno-oncology
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi
BD Announces Early Access Program for BD Resolve™ Single-Cell Analysis Platform
Precision Medicine Unlocks the Future of Targeted Therapy in the Global Healthcare Industry Finds Frost & Sullivan
Sciformix Corporation Receives Prestigious 2017 Global Outsourcing Customer Service Leadership Award from Frost & Sullivan
Arven Pharmaceuticals Selects GE Healthcare’s FlexFactory to Improve Turkish and Regional Access to Biopharmaceuticals
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma
Cost-Containment and Client-Centric Services Catalyse European Custom Procedure Trays and Packs Market Finds Frost & Sullivan
New BD Institute for Medication Management Excellence Aims to Improve Patient Safety and Outcomes through Collaboration
New Varicose Vein Treatment Offers Minimally Invasive Non Surgical Procedure to Canadians
Greenphire and Exostar Partner to Deliver Seamless, Secure Access to Clinical Research Site Payment Solution

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)